Follow the Biomark Diagnostics Inc. share price and the full directors' dealings record of the company, a publicly traded company based in Canada. Shares are listed on CA CA, under the oversight of SEDI. Operating in the Health Care sector, Biomark Diagnostics Inc. has logged 18 reports. Market capitalisation: €56.7m. The latest transaction was filed on 3 July 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Maula Bux, Rashid Ahmed. Every trade is accessible without an account.
18
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
42Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2,500 shares@ CA$0.5877.8% of flowCommon SharesTSXSEDI:4722442
Ideal exit: 13 Feb 2027 (T+270)
18 of 18 declarations
About Biomark Diagnostics Inc.
Biomark Diagnostics Inc. is a company focused on developing diagnostic tests for cancer. It aims to improve patient outcomes through innovative solutions.